|
WO2017040916A2
|
|
Modulation of gpr124 for reduction of pathological fibrosis
|
|
WO2014009251A1
|
|
Method for adjusting the dispensing height of pipettes
|
|
WO2011138265A2
|
|
Indole and indazole derivatives as orexin receptor antagonists
|
|
WO2011138266A1
|
|
Indolizine and imidazopyridine derivatives as orexin receptor antagonists
|
|
WO2011073269A1
|
|
Piperidine aryl sulfonamide derivatives as kv1.3 modulators
|
|
WO2011073273A1
|
|
Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators
|
|
WO2011073277A1
|
|
PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS Kv1.3 MODULATORS
|
|
WO2011073276A1
|
|
Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators
|
|
WO2010133544A1
|
|
Piperazine and aminopyrrolidine compounds as histamine h3 receptor antagonists
|
|
WO2010130638A1
|
|
Sulfonamide compounds, pharmaceutical compositions and uses thereof
|
|
CA2751239A1
|
|
Azetidines as histamine h3 receptor antagonists
|
|
CA2737038A1
|
|
Amide compounds, compositions and uses thereof
|
|
GB0914322D0
|
|
Compounds for treating cancer
|
|
EP2300422A1
|
|
Azetidines as histamine h3 receptor antagonists
|
|
US2011046130A1
|
|
Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
|
|
EP2240467A1
|
|
Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
|
|
EP2215054A1
|
|
Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
|
|
EP2136639A1
|
|
Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
|
|
CN101677569A
|
|
2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof
|
|
US2008270073A1
|
|
Method for detecting the impacts of interfering effects on experimental data
|
